Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease

American Journal of Pathology

Volumn 175, Issue 5, 2009, Pages 2089-2098

  Deng, Yanqiu ^a,b   Li, Bin ^a   Liu, Ying ^a   Iqbal, Khalid ^a   Grundke Iqbal, Inge ^a   Gong, Cheng Xin ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; N ACETYLGLUCOSAMINE; STREPTOZOCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; MALE; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT;

EID: 73649112749     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090157     Document Type: Article

References (67)

1. Iqbal K, Grundke-Iqbal I: Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathol (Berl) 2005, 109:25-31
2. Hoyer S: Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol 2004, 541:135-152
3. Li X, Lu F, Wang JZ, Gong CX: Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci 2006, 23:2078-2086
4. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX: O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101:10804-10809
5. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K: Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. J Alzheimers Dis 2006, 9:1-12
6. Gerozissis K: Brain insulin, energy and glucose homeostasis: genes, environment and metabolic pathologies. Eur J Pharmacol 2008, 585:38-49
7. Gasparini L, Netzer WJ, Greengard P, Xu H: Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 2002, 23:288-293
8. Baki L, Neve RL, Shao Z, Shioi J, Georgakopoulos A, Robakis NK: Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J Neurosci 2008, 28:483-490
9. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 2005, 7:63-80
10. Zhu X, Perry G, Smith MA: Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J Alzheimers Dis 2005, 7:81-84
11. Nitsch R, Hoyer S: Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 1991, 128:199-202
12. Duelli R, Schrock H, Kuschinsky W, Hoyer S: Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci 1994, 12:737-743
13. Lannert H, Hoyer S: Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998, 112:1199-1208
14. Tatebayashi Y, Iqbal K, Grundke-Iqbal I: Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. J Neurosci 1999, 19:5245-5254
15. Gong CX, Wang JZ, Iqbal K, Grundke-Iqbal I: Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neurosci Lett 2003, 340:107-110
16. Bensadoun A, Weinstein D: Assay of proteins in the presence of interfering materials. Anal Biochem 1976, 70:241-250
17. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K: Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 2000, 275:5535-5544
18. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF: The PTEN/ PI3K/AKT signalling pathway in cancer: therapeutic implications. Curr Cancer Drug Targets 2008, 8:187-198
19. McKay MM, Morrison DK: Integrating signals from RTKs to ERK/ MAPK. Oncogene 2007, 26:3113-3121
20. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX: Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 2008, 582:359-364
21. Kreppel LK, Hart GW: Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem 1999, 274:32015-32022
22. Otvos L Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM: Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 1994, 39:669-673
23. Wang J, Tung YC, Wang Y, Li XT, Iqbal K, Grundke-Iqbal I: Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 2001, 507:81-87
24. Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G: Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 2004, 61:3057-3075
25. Deng Y, Li B, Liu F, Iqbal K, Grundke-Iqbal I, Brandt R, Gong CX: Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. FASEB J 2008, 22:138-145
26. Schechter R, Abboud M: Neuronal synthesized insulin roles on neural differentiation within fetal rat neuron cell cultures. Brain Res Dev Brain Res 2001, 127:41-49
27. Schechter R, Beju D, Gaffney T, Schaefer F, Whetsell L: Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. Brain Res 1996, 736:16 -27
28. Banks WA: The source of cerebral insulin. Eur J Pharmacol 2004, 490:5-12
29. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G: Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994, 91:5710-5714
30. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweier JL, Stern D: Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1995, 1:693-699
31. Smith MA, Sayre LM, Perry G: Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link. Diabetologia 1996, 39:247
32. Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S: Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 2007, 101:757-770
33. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J: Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005, 2:3-18
34. Takashima A: GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2006, 9:309-317
35. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K: Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 1996, 92:232-241
36. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF: Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999, 58:1010-1019
37. Liu F, Liang Z, Shi J, Yin D, El-Akkad E, Grundke-Iqbal I, Iqbal K, Gong CX: PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett 2006, 580:6269-6274
38. Liu F, Li B, Tung EJ, Grundke-Iqbal I, Iqbal K, Gong CX: Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci 2007, 26:3429-3436
39. Ho GJ, Drego R, Hakimian E, Masliah E: Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 2005, 4:247-256
40. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Vinals F, Ribalta T: Phosphorylated map kinase (ERK1. ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001, 11:144-158
41. Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, Grundke-Iqbal I: Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res 2002, 109:45-55
42. Scheepers A, Joost HG, Schurmann A: The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004, 28:364-371
43. McEwen BS, Reagan LP: Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004, 490:13-24
44. Kalaria RN, Harik SI: Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 1989, 53:1083-1088
45. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P: Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994, 35:546-551
46. Mooradian AD, Chung HC, Shah GN: GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging 1997, 18:469-474
47. Wells L, Hart GW: O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS Lett 2003, 546:154-158
48. Zachara NE, Hart GW: O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim Biophys Acta 2004, 1673:13-28
49. Slawson C, Hart GW: Dynamic interplay between O-GlcNAc and O-phosphate: the sweet side of protein regulation. Curr Opin Struct Biol 2003, 13:631-636
50. Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, Whitworth GE, Stubbs KA, McEachern EJ, Davies GJ, Vocadlo DJ: A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 2008, 4:483-490
51. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K: Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol 2006, 2006:31825
52. Wang JZ, Liu F: Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 2008, 85:148-175
53. Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I, Ramakrishna N, Gong CX: Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 2008, 22:3224-3233
54. Yu Y, Run X, Liang Z, Li Y, Liu F, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX: Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem 2009, 108:1480-1494
55. Mondragon-Rodriguez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI, Avila J, Smith MA, Perry G, Garcia-Sierra F: Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol 2008, 89:81-90
56. Alonso AD, Zaidi T, Grundke-Iqbal I, Iqbal K: Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:5562-5566
57. Alonso AD, Grundke-Iqbal I, Iqbal K: Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996, 2:783-787
58. Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K: Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 1997, 94:298-303
59. Alonso AD, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K: Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 2001, 98:6923-6928
60. Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, Miyakawa T: Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 1996, 7:177-181
61. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002, 103:26-35
62. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E: Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 1998, 252:542-552
63. Blondel O, Portha B: Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats. Diabete Metab 1989, 15:382-387
64. Kadowaki T, Kasuga M, Akanuma Y, Ezaki O, Takaku F: Decreased autophosphorylation of the insulin receptor-kinase in streptozotocin-diabetic rats. J Biol Chem 1984, 259:14208-14216
65. Salkovic-Petrisic M, Hoyer S: Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach, J Neural Transm Suppl 2007, 217-233
66. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ: Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 2002, 83:1529-1533
67. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F: Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 2006, 27:1258-1268